Market Newsdesk

SAN FRANCISCO, Aug. 25, 2025 (GLOBE NEWSWIRE) — A federal court has reopened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, setting a new deadline of September 24, 2025. This comes after the previous lead plaintiff was disqualified in an order on August 4, 2025.

Hagens Berman urges Spectrum investors who suffered substantial losses to submit your losses now.

Class Period: Mar. 17, 2022 – Sept. 22, 2022
Lead Plaintiff Deadline: Sept. 24, 2025
Visit:www.hbsslaw.com/investor-fraud/sppi  
Contact the Firm Now:[email protected]
844-916-0895

Background of the Lawsuit

The lawsuit, Christiansen v. Spectrum Pharmaceuticals, Inc., et al., has been ongoing since late 2022 and early 2023. At that time, multiple class actions were filed against the company, alleging that it made misleading statements about a drug called poziotinib. The court consolidated these cases and in March 2023, appointed an individual investor as the lead plaintiff. The case has since survived a motion to dismiss and moved into the discovery phase.

Now, with the lead plaintiff disqualified, the court is once again seeking a new representative for investors who purchased Spectrum stock between March 17, 2022, and September 22, 2022, and suffered losses.

The core of the litigation alleges that Spectrum repeatedly assured investors of positive data from its poziotinib clinical trial. However, the complaint claims the company omitted crucial information, including negative safety and efficacy data and the fact that it had not enrolled any patients in a required Phase 3 trial. These details were allegedly revealed when the FDA Oncologic Drugs Advisory Committee released a briefing document in September 2022, causing Spectrum’s stock price to crash.

Your Opportunity to Act

National shareholders’ rights firm Hagens Berman is investigating these claims. We encourage Spectrum (SPPI) investors who suffered significant losses to contact us about becoming the new lead plaintiff. As lead plaintiff, you would play a critical role in overseeing the litigation and protecting the interests of all class members.

If you’d like more information and answers to frequently asked questions about the Spectrum Pharmaceuticals case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Spectrum should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Contact:

Reed Kathrein, 844-916-0895

Beijing, China, Aug. 25, 2025 (GLOBE NEWSWIRE) —  Kuke Music Holding Limited (“Kuke” or the “Company”) (NYSE: KUKE), a leading classical music service platform in China, today published a notice to announce that it will hold an extraordinary general meeting (the “EGM”) of shareholders (the “EGM Notice”) at 10:30 am, Beijing Time, on September 12, 2025 at 25-1, Beijing Music Industrial Park, Heizhuanghu Road, Chaoyang District, Beijing, 100020 People’s Republic of China (or after the Class B Meeting, as defined below, whichever is later), for the purposes of considering and, if thought fit, passing the resolutions set forth in the EGM Notice. The EGM Notice and form of proxy for the EGM are available on the Company’s website at https://ir.kuke.com/, as well as on the SEC’s website at www.sec.gov.

The Company will hold a class meeting of holders of Class B ordinary shares with a par value of US$0.001 each (the “Class B Meeting”) for the purposes of considering and, if thought fit, passing the resolution set forth in the notice of the Class B Meeting. The Class B Meeting will be held at the same venue and on the same date as the EGM, at 9:30 am, Beijing Time. The notice of and form of proxy for the Class B Meeting are available on the Company’s website at https://ir.kuke.com/, as well as on the SEC’s website at www.sec.gov.

The EGM will consider the following key proposals:

• Amendment of Voting Rights: A special resolution (which shall also include the affirmative votes of holders of at least a majority of the Class A Ordinary Shares) and subject to the passing of the special resolution at the Class B Meeting, to amend the Company’s Articles of Association to change the voting rights of Class B ordinary shares from fifty (50) votes per share to one thousand (1,000) votes per share;

• Removal of Director: An ordinary resolution to remove Yu Chen as a director of the Company pursuant to Article 85(6) of the Articles with immediate effect;

• Written Resolutions Amendment: A special resolution to amend the Articles of Association to permit ordinary and special resolutions of shareholders to be passed by written shareholder resolutions signed by such majority or all shareholders as permitted under Cayman Islands law; and

• Adoption of Fourth Amended and Restated Articles: A special resolution, subject to approvals of Proposals 1 and 3, to adopt fourth amended and restated articles of association incorporating all approved amendments with effect immediately after the close of the EGM.

Holders of record of the Company’s ordinary shares at the close of business on August 18, 2025, Eastern Time are entitled to attend, and to vote at, the EGM and any adjournment thereof, and, as applicable, the Class B Meeting. Holders of record of the Company’s American depositary shares (the “ADSs”) at the close of business on August 18, 2025, Eastern Time who wish to exercise their voting rights for the underlying ordinary shares must give voting instructions to Deutsche Bank Trust Company Americas, the depositary of the Company’s ADS program.

About Kuke Music Holding Limited

Kuke is a leading classical music service platform in China encompassing the entire value chain from content provision to music learning services. By collaborating with its strategic global business partner Naxos, the largest independent classical music content provider in the world, the foundation of Kuke’s extensive classical music content library is its unparalleled access to more than 900 top-tier labels and record companies. Leveraging its market leadership in international copyrighted classical music content, Kuke provides highly scalable classical music licensing services to various online music platforms, and classical music subscription services to over 800 universities, libraries, and other institutions across China. In addition, it has hosted Beijing Music Festival (“BMF”), the most renowned music festival in China, for 24 consecutive years. Through KUKEY, the Company’s proprietary smart music learning solutions, Kuke aims to democratize music learning via technological innovation, bring fascinating music content and professional music techniques to more students, and continuously improve the efficiency and penetration of music learning in China. For more information about Kuke, please visit https://ir.kuke.com/.

Forward-looking Statements

This announcement contains forward looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” “potential,” “continue” or other similar expressions. Statements that are not historical facts, including but not limited to statements about Kuke’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including those in Kuke’s registration statements filed with the U.S. Securities and Exchange Commission. Further information regarding these and other risks is included in Kuke’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Kuke undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For further information, please contact:

Kuke Music Holding Limited
Investor Relations
Email: [email protected]

– U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026

– Patient dosing expected to begin in Australia in Q4 2025

HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, today announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA), the FDA’s written feedback supports advancing SER-252 (POZ-apomorphine) in a registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway.

“People living with advanced Parkinson’s need more consistent relief from motor fluctuations and our data to date suggest that SER-252 may reliably improve daily function,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “Based on the FDA’s written feedback, we plan to advance SER-252 on a registration-directed 505(b)(2) NDA regulatory pathway. Our development plan is designed to be rigorous and capital efficient. We aim to streamline a potential NDA while generating the clinical and pharmacologic evidence to support regulatory review and improve patients’ lives.”

In its discussions with the FDA, Serina outlined a program designed to leverage prior knowledge of apomorphine utilizing the company’s POZ-enabled profile. Serina plans to include a pharmacokinetic (PK) bridging component to an approved apomorphine product, consistent with a 505(b)(2) NDA strategy. The FDA’s feedback indicates that Serina’s initial study may be designed and conducted as a component of a registrational trial program, subject to standard clinical and nonclinical requirements and finalization of documentation at the time of IND submission.

“Beyond SER-252, we are advancing a pipeline of POZ-enabled small molecules that may follow similar 505(b)(2) NDA pathways where appropriate,” said Mr. Ledger. “The FDA’s feedback provides early proof-of-principle for our platform, confirming that we can effectively align with the agency’s expectations for the 505(b)(2) NDA regulatory pathway. Each program will follow its own science and require FDA dialogue, but our goal remains to unlock new possibilities in treatment and deliver better options to patients as quickly as possible.”

Upcoming Regulatory and Clinical Milestones

Serina plans to submit the U.S. IND application in Q4 2025 incorporating the FDA’s recommendations. In parallel, the company expects to begin dosing patients in Australia in Q4 2025 as part of the global registrational program, with data from these patients expected to contribute to the overall data package for regulatory review and potential approval. Following U.S. IND clearance, Serina anticipates initiation of enrollment in the U.S. in Q1 2026.

SER-252 Registrational Study Design Overview

The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose (five cohorts of eight; n=40) and multiple-ascending-dose components (up to three cohorts of sixteen; n=48) in adults with Parkinson’s disease and motor fluctuations. The study is designed to evaluate safety, tolerability, and pharmacokinetics of subcutaneous SER-252 versus placebo, with exploratory efficacy measures that include MDS-UPDRS motor scores and structured motor-state assessments. Dose escalation will be overseen by a Safety Review Committee and the study will be conducted across sites in the U.S. and Australia.

About SER-252 (POZ-apomorphine)

SER 252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS) via a single or twice-weekly subcutaneous injection. CDS has been shown to reduce the severity of motor fluctuations (which includes levodopa-induced dyskinesia) and enable greater daily on time, with reduced off time, in advanced Parkinson’s patients. SER-252 leverages strategic partner Enable Injections’ enFuse^™ wearable drug delivery platform to enhance patient comfort and convenience, providing CDS to patients via an easy-to-administer, long-acting subcutaneous injection.

About the POZ Platform

^™

Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic profiles that can include severe skin reactions, side effects due to peak-trough variations in drug levels and a short half-life. Serina believes that by using POZ technology, drugs with a narrow therapeutic index can be designed to maintain more desirable and stable levels in the blood. Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform^™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics, and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatx.com.

Cautionary Statement Regarding Forward-Looking Statement

This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs, or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in Serina’s Annual Report on Form 10-K, and Serina’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

For inquiries, please contact:

Stefan Riley
[email protected]
(256) 327-9630

MONROE, Mich., Aug. 25, 2025 (GLOBE NEWSWIRE) — La-Z-Boy Incorporated (NYSE: LZB), a global leader in the retail and manufacture of residential furniture, today declared a quarterly cash dividend of $0.22 per share on the common stock of the company. The dividend will be paid on September 15, 2025, to shareholders of record on September 4, 2025.

Investor Relations Contact

:

Mark Becks, CFA, (734) 457-9538
[email protected] 

About La-Z-Boy

:

La-Z-Boy Incorporated brings the transformational power of comfort to people, homes, and communities around the world – a mission that began when its founders invented the iconic recliner in 1927. Today, the company operates as a vertically integrated furniture retailer and manufacturer, committed to uncompromising quality and compassion for its consumers.

The Retail segment consists of nearly 210 company-owned La-Z-Boy Furniture Galleries® stores and is part of a broader network of nearly 370 La-Z-Boy Furniture Galleries® that, with La-Z-Boy.com, serve customers nationwide. Joybird®, an omni-channel retailer and manufacturer of modern upholstered furniture, has 14 stores in the U.S. (one new store opened in fiscal 2026 Q2). In the Wholesale segment, La-Z-Boy manufactures comfortable, custom furniture for Furniture Galleries® and a variety of retail channels, England Furniture Co. offers custom upholstered furniture, and casegoods brands Kincaid®, American Drew®, and Hammary® provide pieces that make every room feel like home. To learn more, please visit: https://www.la-z-boy.com/.

FARGO, N.D., Aug. 25, 2025 (GLOBE NEWSWIRE) — NI Holdings, Inc. (the “Company”, NASDAQ: NODK) announced today that its Board of Directors has approved an authorization for the repurchase of up to approximately $5 million of the Company’s outstanding common stock. This supports our planned approach to capital deployment to create long-term value for our shareholders. This authorization is in addition to the approximately $1.3 million remaining under the Board’s previous repurchase authorization announced on May 9, 2022, for a total of approximately $6.3 million available for the repurchase of the Company’s outstanding common stock.

The actual timing, number, and value of common shares repurchased under the plan will be determined by management in its discretion and will depend on a number of factors, including, among others, general market conditions, the trading price of common shares, and applicable legal requirements. The Company has no obligation to repurchase any common shares under the authorization, and the repurchase plan may be suspended, discontinued, or modified at any time for any reason.

NI Holdings, Inc. had 20,675,337 shares of common stock outstanding as of July 31, 2025, per the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2025.

About the Company


NI Holdings, Inc. is an insurance holding company. The Company is a North Dakota business corporation that is the stock holding company of Nodak Insurance Company and became such in connection with the conversion of Nodak Mutual Insurance Company from a mutual to stock form of organization and the creation of a mutual holding company. The conversion was consummated on March 13, 2017. Immediately following the conversion, all of the outstanding shares of common stock of Nodak Insurance Company were issued to Nodak Mutual Group, Inc., which then contributed the shares to NI Holdings in exchange for 55% of the outstanding shares of common stock of NI Holdings. Nodak Insurance Company then became a wholly-owned stock subsidiary of NI Holdings. NI Holdings’ financial statements are the consolidated financial results of NI Holdings; Nodak Insurance, including Nodak’s wholly-owned subsidiaries American West Insurance Company, Primero Insurance Company, and Battle Creek Insurance Company; Direct Auto Insurance Company; and Westminster Insurance Company until the date of sale.

Safe Harbor Statement


Some of the statements included in this news release, particularly those relating to potential future repurchases of the Company’s stock are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Actual results could vary materially. Factors that could cause actual results to vary materially include: our ability to maintain profitable operations, the adequacy of the loss and loss adjustment expense reserves, business and economic conditions, the changes in the international trade policies and the potential impact of such changes, interest rates, competition from various insurance and other financial businesses, terrorism, the availability and cost of reinsurance, adverse and catastrophic weather events, including the impacts of climate change, legal and judicial developments, changes in regulatory requirements, our ability to integrate and manage successfully the insurance companies we may acquire from time to time, the impact of inflation on our operating results, and other risks we describe in the periodic reports we file with the SEC. You should not place undue reliance on any such forward-looking statements. We disclaim any obligation to update such statements or to announce publicly the results of any revisions that we may make to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, as filed with the SEC.

Investor Relations Contact:


Matt Maki

Executive Vice President, Treasurer and Chief Financial Officer

701-212-5976

[email protected]

FREMONT, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) — SoundThinking, Inc. (Nasdaq: SSTI), a leading public safety technology company, announced today that the Company will present at the 2025 Annual Gateway Conference, which is being held September 3-4, 2025, at the Four Seasons Hotel in San Francisco, CA.

SoundThinking’s management team will present on Thursday, September 4th at 11:00 a.m. Pacific Time (PT). The presentation will be webcast live and available for replay here. In addition to the presentation, SoundThinking executives will be available for one-on-one meetings with investors throughout the conference.

For additional information or to schedule a meeting with management, please contact SoundThinking’s investor relations team at [email protected].

About SoundThinking

SoundThinking, Inc. (Nasdaq: SSTI) is a leading public safety technology company that delivers AI- and data-driven solutions for law enforcement, civic leadership, and security professionals. SoundThinking is trusted by more than 300 customers and has worked with approximately 2,100 agencies to drive more efficient, effective, and equitable public safety outcomes. The company’s SafetySmart^TM platform includes ShotSpotter®, the leading acoustic gunshot detection system; CrimeTracer^TM, the leading law enforcement search engine; CaseBuilder^TM, a one-stop investigation management system; ResourceRouter^TM, software that directs patrol and community anti-violence resources to help maximize their impact; SafePointe®, an AI-based weapons detection system; and PlateRanger^TM powered by Rekor®, a leading ALPR solution. SoundThinking has been designated a Great Place to Work® company.

Company Contact:

Alan Stewart, CFO
SoundThinking, Inc.
+1 (510) 794-3100
[email protected]

Investor Relations Contact:

Ankit Hira
Solebury Strategic Communications for SoundThinking, Inc.
+1 (203) 546-0444
[email protected]

VIRGINIA CITY, Nev., Aug. 25, 2025 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock,” “our,” and the “Company”), today announced that on August 15, 2025, immediately following the Company’s previously announced successful public equity offering, that it had immediately placed all of the purchase orders and paid deposits totaling $5.1 million toward the purchase of all of the equipment for its 100,000 ton per year, certified zero-landfill industry-scale solar panel recycling facility to be located in Silver Springs, Nevada. The total purchase price for all the equipment is approximately $10.5 million. The Company also plans on spending an additional $1.5 million for expanded storage capacity, utility upgrades and commissioning of the facility.

“Our equity offering represented a remarkably broad and deep representation of some of the best institutional investors with proceeds dedicated to funding the capital expenditures for our first industry-scale facility, the operating expenses required to reach sustained profitability and the extinguishment of debt and other obligations. Our balance sheet has never been stronger as we are now rapidly deploying our industry leading technology and customer solutions,” stated Corrado De Gasperis, Executive Chairman and CEO of Comstock Inc. “The recycling growth opportunities have developed better and faster than our original plans, and we have now attracted some of the most sophisticated partners for investment, feedstock, operations, and offtake.”

Comstock Metals has now been operating its first commercial demonstration facility for over 18 months and in November of 2024, submitted permits for the first industry-scale photovoltaic recycling facility.  Comstock Metals’ billable revenues are expected to be eight times greater in 2025, as compared to 2024, or currently projected to be over $3.5 million, with proportionate future increases in 2026, as we scale up our first industry-scale facility. 

The Company’s solar panel recycling objectives for the next 10 months include:

• Expand and activate local county storage capacity adjacent to our first industry-scale facility;
• Complete permitting for our first industry-scale facility in Silver Springs, NV, by November 2025;
• Secure additional Master Service Agreements (MSA) with national and regional customers;
• Complete site selection and permit submissions for two additional solar panel recycling locations;
• Expand our system globally with strategic and/or international partners;
• Procure, deploy, and assemble plant and equipment for our first industry-scale facility during Q4 2025;
• Commission the industry-scale facility during Q1 2026;
• Continuously operate the zero-landfill industry-scale solar panel recycling facility during Q2 2026; and
• Advance and expand R&D efforts to recover more and higher-purity materials from recycled streams for offtake.

“For the remainder of 2025, we plan on accelerating and increasing our lead as our solar panel recycling systems rapidly expand market share nationally while we await our final permits and the delivery of our high-speed, continuous processing system,” said Comstock Metals’ President, Dr. Fortunato Villamagna. “With our system, every component of an end-of-life solar panel (glass, aluminum, semiconductor fines, and other metals) is fully and cleanly reclaimed and repurposed into new, salable raw materials.”

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies that enable, support and sustain clean energy systems across entire industries by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable electrification metals, like silver, aluminum, copper, and other critical minerals from end-of-life photovoltaics.

To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
[email protected]

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
[email protected]

Forward-Looking Statements
 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; divestitures, spin-offs or similar distribution transactions, future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, divestitures, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Houston, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced that it received notice from the NYSE American LLC confirming acceptance of the Company’s Plan to regain compliance with its continued listing standards, including granting a Plan period through November 30, 2026, for the Company to execute its compliance strategy.

As previously disclosed in the Company’s Current Report on Form 8-K filed on June 2, 2025, Battalion received a notice from the NYSE American indicating noncompliance with the continued listing standards set forth in Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. In response, the Company submitted a detailed plan to regain compliance, which was accepted on August 19, 2025.

During the Plan period, NYSE American staff will monitor the Company’s progress. If Battalion fails to make progress consistent with the plan, the NYSE American may initiate delisting procedures, regardless of the Company’s listing status at that time.

The Company’s common stock will continue to be listed on the NYSE American under the symbol “BATL,” pursuant to an exception, and remains subject to compliance with all other applicable listing requirements.

Management Comments

“We appreciate the NYSE American’s acceptance of our compliance plan and the opportunity to demonstrate our commitment to restoring compliance,” said Matt Steele, Chief Executive Officer of Battalion Oil Corporation. “Our team is focused on executing the plan with discipline and urgency, while continuing to strengthen our operations and financial position. We remain confident in our long-term strategy and are committed to delivering value to our shareholders.”

While the Company is committed to regaining compliance, there can be no assurance that it will be successful within the Plan period. Future developments may also impact the Company’s ability to meet continued listing standards or comply with other NYSE American requirements.

Forward Looking Statements

This press release includes forward-looking statements as defined by U.S. securities laws. These statements are not historical facts and often include words like “expects,” “believes,” “plans,” “estimates,” “may,” “will,” or similar expressions. They cover topics such as future production, financial condition, capital spending, and strategic plans. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ significantly. Key risks are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and other filings with the Securities and Exchange Commission (SEC), available at www.sec.gov or on the Company’s website at www.battalionoil.com. Readers are cautioned not to rely too heavily on these forward-looking statements, which speak only as of the date of this release. The Company does not undertake any obligation to update these statements in light of new information or future events.

BATTALION OIL CORPORATION
Matthew B. Steele
Chief Executive Officer
832-538-0300 | www.battalionoil.com